SAN FRANCISCO, CA – December 12, 2023 – A groundbreaking new study, known as WISDOM, has delivered compelling evidence that tailoring breast cancer screening strategies to a woman’s individual risk profile is not only safer but significantly more effective than the long-standing practice of routine annual mammograms for everyone. Published today in JAMA and presented concurrently at the prestigious San Antonio Breast Cancer Symposium, these findings are poised to reshape clinical guidelines and transform how millions of women approach breast cancer prevention and early detection.
The multi-institutional research, coordinated by the University of California San Francisco (UCSF), suggests a profound shift away from rigid, age-based screening protocols toward a dynamic system grounded in comprehensive risk evaluation. By matching screening intensity and frequency to personal risk levels, researchers demonstrated a notable reduction in the diagnosis of more advanced cancers, ensuring that individuals receive precisely the level of surveillance and preventative care they need, optimizing resource allocation and minimizing potential harms associated with over-screening.
The Imperative for Change: Moving Beyond Age-Centric Screening
For decades, breast cancer screening guidelines in the United States have largely operated under a one-size-fits-all paradigm, primarily relying on a woman’s age as the decisive factor for initiating and continuing mammography. This approach, while foundational in improving early detection, has faced increasing scrutiny as scientific understanding of breast cancer risk has evolved. Research has consistently highlighted the vast heterogeneity in individual risk, influenced by a complex interplay of genetic predispositions, lifestyle choices, personal health history, and breast tissue characteristics. The traditional model, by treating most women as if they faced similar risk, often led to unnecessary anxiety and procedures for those at low risk, while potentially under-screening individuals with substantially elevated risk.
The WISDOM study, an acronym for Women Informed to Screen Depending on Measures of Risk, emerged from this critical need to modernize screening paradigms. Launched in 2016, the study directly confronted the limitations of age-based screening by comparing it against an individualized, risk-stratified approach. The ultimate goal was to determine if a personalized strategy could maintain or improve early detection rates while reducing potential harms like false positives, over-diagnosis, and unnecessary biopsies, particularly for lower-risk populations. UCSF, a global leader in medical research and breast cancer care, served as the coordinating center, marshalling expertise from numerous institutions across the nation to execute this ambitious undertaking.
Unveiling the WISDOM Methodology: A Deeper Dive into Risk Assessment
The initial phase of the WISDOM study gathered extensive data from 46,000 women across the United States, meticulously comparing the efficacy of traditional annual mammography against a personalized, risk-based screening strategy. At the heart of the personalized approach was a sophisticated risk assessment model that integrated multiple validated factors to provide a truly individualized risk profile for each participant. This went far beyond simple age and family history, encompassing:
- Age: While not the sole determinant, age remains a component of overall risk.
- Genetic Information: This included testing for well-known pathogenic variants like BRCA1 and BRCA2, as well as evaluating smaller, common DNA changes that, when combined, form a polygenic risk score (PRS). PRS significantly enhanced the precision of risk prediction by quantifying the cumulative effect of multiple low-impact genetic variations.
- Lifestyle Factors: Habits such as alcohol consumption, physical activity levels, diet, and weight were factored into the risk assessment.
- Health History: Personal medical history, including previous breast biopsies, benign breast conditions, and reproductive history (e.g., age at first menstruation, age at first live birth, menopausal status), contributed to the overall risk calculation.
- Breast Density: Known to be an independent risk factor for breast cancer and a factor that can obscure cancers on mammograms, breast density was also incorporated.
Based on this comprehensive evaluation, participants were assigned to one of four distinct risk categories, each with tailored screening recommendations:
- Lowest Risk (26% of participants): Women in this group were advised to delay routine screening until age 50, or until an algorithmic reassessment indicated their risk had naturally risen to that of a typical 50-year-old woman. This approach aimed to reduce unnecessary early screenings for those with minimal risk.
- Average Risk (62% of participants): The majority of participants fell into this category, for whom biennial (every two years) mammograms were recommended. This aligns with guidelines from some organizations, but the decision was based on a personalized risk assessment rather than a blanket age recommendation.
- Elevated Risk (8% of participants): For these women, annual mammograms were advised, reflecting their higher propensity for developing breast cancer.
- Highest Risk (2% of participants): This group, comprising women with significantly elevated risk factors, received the most intensive screening protocol. They were advised to undergo screening twice a year, alternating between mammography and magnetic resonance imaging (MRI), regardless of their age. MRI is a more sensitive imaging modality, particularly useful for detecting cancers in dense breasts or in high-risk individuals.
Beyond screening, women identified with elevated or highest risk also received personalized guidance on strategies to lower their chances of developing breast cancer. This proactive prevention component included access to an online decision-making tool focused on breast health, as well as direct consultations with a breast health specialist. Recommendations spanned a spectrum of interventions, from actionable lifestyle changes like improving dietary habits and increasing physical activity to in-depth discussions about pharmacological options, such as anti-estrogen medications, known to reduce breast cancer risk in certain populations.
Crucially, the study meticulously tracked outcomes, finding that the personalized screening approach did not lead to a higher rate of late-stage cancer diagnoses. This critical finding underscores the safety and efficacy of moving away from universal annual screening without compromising early detection for those who need it most. Furthermore, the strong acceptance of the personalized approach was evident in the observational group, where participants could choose their preferred screening strategy. A remarkable 89% opted for risk-based screening, signaling a clear preference and confidence in this tailored methodology among the women themselves.
Expert Perspectives: A Paradigm Shift in Practice
The implications of the WISDOM study are far-reaching, prompting leading experts to call for immediate reevaluation of current clinical guidelines.
"These findings should transform clinical guidelines for breast cancer screening and alter clinical practice," asserted Dr. Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author. Dr. Esserman, a long-time advocate for personalized medicine in oncology, emphasized the foundational role of risk assessment. "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies." Her comments highlight the study’s potential to usher in a new era where screening is not just about detection, but also about proactive prevention tailored to an individual’s unique biological landscape.
Breast cancer remains the most commonly diagnosed cancer among women in the United States, excluding non-melanoma skin cancers. The persistent reliance on age as the primary screening determinant, despite decades of research demonstrating wide variations in individual risk, has been a significant point of contention within the medical community. The WISDOM study directly addresses this disparity, providing robust evidence to support a more nuanced and effective strategy.
Co-author Dr. Jeffrey A. Tice, MD, a UCSF professor of Medicine specializing in breast cancer risk assessment tools, underscored the efficiency gains inherent in the personalized approach. "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer," Dr. Tice stated. This reallocation of resources holds significant promise for healthcare systems, potentially reducing the burden of unnecessary tests and associated anxieties for a large segment of the population, while simultaneously intensifying surveillance for those who stand to benefit most from early and aggressive intervention. This could lead to a more sustainable and equitable allocation of healthcare resources.
Expanding the Horizon of Genetic Testing: Unmasking Hidden Risks
One of the most striking and impactful revelations from the WISDOM study concerns the expansion of genetic testing. Since its inception in 2016, the study has enrolled over 80,000 women, with recent expansions to include women as young as 30. This broader inclusion aimed to identify individuals who might face an increased risk of aggressive early cancers due to inherited genetic variants, even without a traditional family history.
The study’s findings in this area were particularly illuminating: a staggering 30% of women who tested positive for a genetic variant linked to a higher breast cancer risk reported absolutely no family history of the disease. Under prevailing clinical guidelines, many of these women would not typically qualify for genetic testing, meaning their elevated risk would remain undetected until a diagnosis of cancer, often at a later, more advanced stage. This finding alone presents a compelling argument for broadening access to genetic testing, integrating it as a standard component of comprehensive risk assessment rather than limiting it to those with a known familial predisposition.
Beyond the well-known pathogenic variants such such as BRCA1 and BRCA2, the WISDOM study also meticulously evaluated the impact of smaller DNA changes. These common genetic variants, when considered collectively, form a polygenic risk score (PRS). The integration of PRS significantly improved the precision of risk predictions, leading to a reclassification of 12% to 14% of participants into a different risk category. This demonstrates the power of advanced genomic tools to fine-tune individual risk assessments, moving beyond single-gene mutations to a more holistic understanding of genetic susceptibility.
"This is one of the first studies to offer genetic testing to all women, regardless of family history," noted co-author Allison S. Fiscalini, MPH, director of the Athena Breast Health Network and the WISDOM study at UCSF. "When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention." Fiscalini’s comments underscore the transformative potential of integrating universal genetic screening into standard practice, paving the way for truly personalized prevention strategies that catch hidden risks before they manifest as disease.
The Path Forward: Refining Risk-Based Screening with WISDOM 2.0
The journey toward fully optimized, personalized breast cancer screening continues with the ongoing WISDOM 2.0 study, which is actively enrolling participants. Building on the foundational insights of the initial phase, WISDOM 2.0 aims to further refine risk assessment models, with a particular focus on better identifying women who face a higher likelihood of developing aggressive forms of breast cancer. The ultimate objective is to provide these high-risk individuals with even more precise and proactive screening and prevention strategies, meticulously tailored to their long-term health needs and specific cancer subtypes.
The collaborative spirit of the WISDOM study, involving numerous investigators from UCSF, UC Los Angeles, UC Irvine, UC San Diego, San Francisco VA Health Care System, Sanford Health in North Dakota, University of Chicago, Diagnostic Center of Miami, University of Alabama, Virginia Commonwealth University, Weill Cornell Medicine in New York, and the Karolinska Institutet in Stockholm, speaks to the broad consensus within the scientific community regarding the importance of this research. Funding from vital organizations such as the Patient Center Outcomes Research Institute, the National Cancer Institute (R01CA237533), and the Breast Cancer Research Foundation further highlights the significance and widespread support for this innovative approach to breast cancer screening.
As the medical community absorbs these pivotal findings, the WISDOM study stands as a beacon for the future of personalized medicine. Its robust data provides a compelling case for a fundamental shift in breast cancer screening, promising a future where each woman’s unique risk profile dictates her path to prevention and early detection, leading to safer, more effective, and ultimately, more equitable outcomes for all.
About the Author
